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Calcium electroporation and 
electrochemotherapy for 
cancer treatment: Importance 
of cell membrane composition 
investigated by lipidomics, 
calorimetry and in vitro efficacy
K. L. Hoejholt1, t. Mužić  2, s. D. Jensen1, L. t. Dalgaard  3, M. Bilgin4, J. Nylandsted  4, 
t. Heimburg  2, s. K. Frandsen1,5 & J. Gehl  1,5,6
Calcium electroporation is a novel anti-cancer treatment investigated in clinical trials. We explored 
cell sensitivity to calcium electroporation and electroporation with bleomycin, using viability assays 
at different time and temperature points, as well as heat calorimetry, lipidomics, and flow cytometry. 
Three cell lines: HT29 (colon cancer), MDA-MB231 (breast cancer), and HDF-n (normal fibroblasts) 
were investigated for; (a) cell survival dependent on time of addition of drug relative to electroporation 
(1.2 kV/cm, 8 pulses, 99 µs, 1 Hz), at different temperatures (37 °C, 27 °C, 17 °C); (b) heat capacity 
profiles obtained by differential scanning calorimetry without added calcium; (c) lipid composition by 
mass spectrometry; (d) phosphatidylserine in the plasma membrane outer leaflet using flow cytometry. 
Temperature as well as time of drug administration affected treatment efficacy in HT29 and HDF-n 
cells, but not MDA-MB231 cells. Interestingly the HT29 cell line displayed a higher phase transition 
temperature (approximately 20 °C) versus 14 °C (HDF-n) and 15 °C (MDA-MB231). Furthermore the HT29 
cell membranes had a higher ratio of ethers to esters, and a higher expression of phosphatidylserine in 
the outer leaflet. In conclusion, lipid composition and heat capacity of the membrane might influence 
permeabilisation of cells and thereby the effect of calcium electroporation and electrochemotherapy.
Electroporation describes the use of brief electric pulses to transiently permeabilise cell membranes allowing 
uptake of otherwise impermeant molecules1. The common feature of electroporation-based therapies is permea-
bilisation of the cell membrane by application of electrical pulses thereby inducing an electric field that exceed the 
transmembrane potential of the plasma membrane.
Electroporation based therapies, utilized as anticancer treatments, include gene therapy2,3, irreversible elec-
troporation4, and electrochemotherapy5,6.
In electrochemotherapy tumor cells are permeabilised by electroporation thereby enhancing their uptake of 
chemotherapeutic drugs (primarily bleomycin and cisplatin are used)1. Electrochemotherapy is currently in use 
in many cancer centers as a safe and efficient treatment of cutaneous and subcutaneous metastases7–10. The use of 
electrochemotherapy for treatment of internal tumors is currently being investigated in clinical trials11–16.
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Calcium electroporation is a novel anti-cancer treatment where supraphysiological doses of calcium are 
internalized by electroporation causing cell death17. The usage of calcium instead of chemotherapeutic drugs 
presents several advantages: it is non-mutagenic, has a long durability, medical professionals other than oncol-
ogists can administer it, and setting aside the cost of electrodes and electroporator it is inexpensive17–20. The low 
cost of treatment, provided affordable electrodes and electroporator are available, is specifically advantageous 
considering that up to 80% of cancers occur in low-income and middle-income countries21. Preclinical investi-
gations of calcium electroporation suggest that calcium electroporation causes cell death associated with acute 
ATP-depletion17,22 and that the treatment can be performed using the same electroporation parameters as applied 
in electrochemotherapy23 and other electroporation parameters24. Importantly calcium electroporation, like elec-
trochemotherapy, shows a difference in sensitivity between normal and malignant cells in vitro25–27 and in vivo28, 
which might be explained in part by differences in membrane repair capacities29. The first clinical trial on calcium 
electroporation was recently published20 with studies on head and neck cancer and keloids now completed.
The time of pore closure after electroporation has been investigated in vitro30–32 and in vivo33 and a window of 
uptake both pre- and post-pulse is described for several molecules including CrEDTA34 and bleomycin5 but not 
for calcium. Permeability of a membrane describes the membrane’s ability to allow passage of molecules from the 
exterior to the interior of the membrane and vice versa. The plasma membrane is a dynamic structure and its per-
meability is affected by membrane composition, temperature, and the concentrations of among others anesthetics 
and calcium35,36. Calcium is known to also affect resealing of a damaged membrane37,38 and to influence the melt-
ing transition of cell membranes35. As calcium electroporation may find importance in the clinic, we decided to 
investigate optimal temperature and time of administration of calcium in relation to electroporation, comparing 
with bleomycin electroporation as control.
We therefore designed a study to investigate (1) the optimal time of calcium addition relative to electropora-
tion in three different cell lines, (2) a possible temperature dependence, and (3) characteristics of these cell lines 
using lipid composition analysis by mass spectrometry (lipidomics), differential scanning calorimetry, and flow 
cytometric analysis.
As described, we compared calcium electroporation to bleomycin electroporation to investigate possible 
differences in the dependency of drug administration before and after electroporation as well as temperature. 
Moreover, the combination of calcium and bleomycin was investigated to examine if addition of calcium would 
change the effect of bleomycin, as evidenced by alteration of the cytotoxic effect of bleomycin.
Results
Influence of temperature and time of drug administration on calcium electroporation, bleomy-
cin electroporation and calcium-bleomycin electroporation. Each cell line was treated with calcium 
electroporation and bleomycin electroporation. As an effect of calcium on the permeability of the membrane, this 
could potentially alter bleomycin toxicity, why the combination of both drugs with electroporation (calcium-ble-
omycin electroporation) was also investigated (Fig. 1).
Drugs were added at five different time points relative to electroporation, which took place at 37 °C, 27 °C 
and 17 °C. Because the cells were only exposed to experimental temperatures for 5 minutes prior to treatment, 
the effect of temperature on the lipid metabolism of the cells is disregarded. Calcium was added to a final con-
centration of 5 mM and bleomycin to a concentration of 10 µM, which are doses used in the literature for in vitro 
studies17,23. The treatment effect was assessed by measuring cell viability and a low viability equaled a high treat-
ment effect. Results from four different negative control conditions are shown in Supplementary Fig. S1. Limited 
effects were observed after treatment with drug alone or electroporation alone compared with untreated controls 
in all cell lines at all tested temperatures. Treatment with calcium alone resulted in 88–119% viability, treatment 
with calcium and bleomycin resulted in 86–113% viability, treatment with bleomycin alone resulted in 80–104% 
viability, and electroporation alone resulted in 70–88% viability, which correlate with previous studies on these 
cell lines39.
The colon cancer cell line (HT29). Figure 1 (top, left graph) shows results from treatment of the HT29 cell line 
with calcium electroporation demonstrating that treatment efficacy was influenced by temperature and time of 
calcium addition relative to electroporation.
A dependency on time of calcium addition was observed for calcium electroporation at all three temperatures. 
When adding calcium 5 minutes before electroporation treatment effect was significantly greater than when add-
ing calcium 30 or 60 seconds after electroporation regardless of treatment temperature being 37 °C (p < 0.05), 
27 °C (p < 0.05), or 17 °C (p < 0.0001).
A statistically significant difference in treatment effect between the 3 temperatures was only found at one of 
the investigated time points; addition of calcium at 30 seconds after electroporation resulted in treatment effect 
that was significantly lower at 17 °C than at 27 °C (p < 0.05). Importantly, there was no difference in treatment 
effect between the 3 temperatures, when calcium was added before electroporation (Fig. 1, top, left graph).
The effect of bleomycin electroporation (Fig. 1, top, right graph) was only significantly influenced by time of 
drug administration, when bleomycin was added 30 seconds after electroporation instead of 5 minutes before 
at 17 °C (p < 0.05). Surprisingly, when adding bleomycin 5 minutes before electroporation, treatment effect was 
significantly lower at 37 °C than at both 27 °C and 17 °C (p < 0.005).
Treatment of the HT29 cell line with calcium-bleomycin electroporation (Fig. 1, top, middle graph) generated 
results similar to those from treatment with calcium electroporation showing that time of drug administration 
and temperature influenced treatment efficacy. Addition of calcium and bleomycin 5 minutes before electro-
poration resulted in significantly higher treatment effect than addition of calcium and bleomycin at 15, 30, or 
60 seconds after electroporation regardless of treatment temperature being 37 °C (p < 0.005), 27 °C (p < 0.05), or 
17 °C (p < 0.0001).
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Figure 1. Electroporation treatment of three cell lines. HT29 (human colon cancer; top panel), MDA-MB231 
(human breast cancer; middle panel) and HDF-n (human dermal fibroblast; bottom panel) treated with calcium 
electroporation (left), calcium-bleomycin electroporation (middle), and bleomycin electroporation (right). 
Drug was added at different time points relative to electroporation and experiments were performed at different 
temperatures (37 °C, 27 °C, and 17 °C). On the HT29 cell line treatment effect of calcium electroporation or 
calcium-bleomycin electroporation was dependent on temperature and time of drug administration whereas 
treatment effect of bleomycin electroporation was independent on time of addition but showed dependency 
on temperature when bleomycin was added before electroporation. Treatment at 27 °C resulted in highest 
treatment effect for this cell line. Treatment of MDA-MB231 showed neither temperature nor time of addition 
dependency for any of the treatments investigated. On the HDF-n cell line treatment effect of calcium 
electroporation or calcium-bleomycin electroporation was dependent on time of drug administration and 
on temperature whereas treatment effect when treating with bleomycin electroporation was independent on 
temperature and time of drug administration. Treatment at 37 °C resulted in lowest survival for this cell line. 
Results from control samples are shown in Supplementary Fig. S1. Mean + SD, n = 5–8, each performed as 
individual experiments. Obvious outliers have been removed from the data set. Statistical comparisons (two-
way ANOVA) are described in the results section.
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The breast cancer cell line (MDA-MB231). The treatment effect on the MDA-MB231 cell line was independent 
of both temperature and time of drug administration for calcium electroporation, bleomycin electroporation, and 
calcium-bleomycin electroporation (Fig. 1, middle panel).
The normal dermal fibroblast cell line (HDF-n). Results from treatment of the HDF-n cell line with calcium 
electroporation (Fig. 1, bottom, left graph) showed that treatment effect was dependent on temperature and, at 
37 °C also on time of calcium administration. At 37 °C, the treatment effect decreased significantly when calcium 
was added 60 seconds after electroporation compared to addition of calcium 5 minutes before electroporation 
(p < 0.05). When calcium was added before electroporation (5 minutes before or 1 second before) the treatment 
effect was significantly higher at 37 °C than at 17 °C (p < 0.05).
Treatment of the HDF-n cell line with bleomycin electroporation showed no dependency on temperature or 
time of drug administration (Fig. 1, bottom, right graph).
When the normal cell line was treated with calcium-bleomycin electroporation (Fig. 1, bottom, middle graph) 
a dependency on temperature and, at 37 °C also on time of drug administration was observed similar to those 
seen with calcium electroporation. At 37 °C, treatment effect again decreased significantly when calcium and 
bleomycin was added 60 seconds after electroporation compared to addition of calcium and bleomycin 5 minutes 
before electroporation (p < 0.0001). A significant difference in treatment efficacy between 37 °C and 17 °C, with 
37 °C resulting in the highest cell kill, was observed when adding drugs 5 minutes before (p < 0.01), or 15 seconds 
after (p < 0.05) electroporation.
Investigations of cell membrane heat capacity and lipid composition. As the cell lines reacted 
differently to changes in temperature and time of calcium addition and as we hypothesized this difference to be 
caused by differences in cell membrane characteristics, we wanted to further investigate the cell membranes of the 
three cell lines. Thus, the following experiments were performed on the plasma membranes of the three cell lines: 
a) differential scanning calorimetry (DSC) to investigate the change in heat capacity of the cell membranes in 
response to changes in temperature, b) lipidomics performed with mass spectrometry to investigate differences in 
the lipid composition of the cell membranes, c) flow cytometry to investigate the exposure of phosphatidylserine 
in the outer leaflet of the cell membranes.
Differential scanning calorimetry (DSC). The assumption is that a maximum in the heat capacity of the cell 
membrane is correlated with a high lateral compressibility36,40, which may facilitate electropore formation in the 
cells. If a pore is created, its environment is compressed and work is performed. In the absence of an electrical 
field, the free energy ∆F (work) of pore formation is given by
κ
∆ = ⋅ ∆F
A
A1
2
1
T
A
2
where κT
A is the area compressibility, A is the area of the membrane, and ∆A is the area of the pore. This implies 
that the free energy of the pore is lower when the area compressibility is high and it is easier to create a pore41,42. 
A cell membrane can be described as having two temperature dependent phases, (1) a gel-like phase (low perme-
ability) and (2) a fluid phase (permeability higher than in the gel-phase). The two phases are separated by a phase 
transition42 in which the plasma membrane reaches its maximum permeability42–44. The transition is an 
order-disorder transition within the lipid membranes and not a transition of the cells as a whole40,42.
All three cell lines displayed these phases (Fig. 2), but interestingly the HT29 cell line displayed a higher phase 
transition temperature (approximately 20 °C) versus MDA-MB231 (approximately 15 °C) and HDF-n (approx-
imately 14 °C). This means that the phase transition of the colon cancer cell line occurred within the tempera-
ture range investigated (17–37 °C) meaning that between the temperatures investigated this cell line underwent 
changes in plasma membrane permeability.
The difference between the heat capacity profiles indicated that the three cell lines have cell membranes of 
different composition, which would affect the cell membranes’ reactions to changes in temperatures and to elec-
troporation. This may be part of the explanation for the differential effects of calcium electroporation observed 
between the three cell lines in electroporation experiments. Though the phase transition temperature of the 
HDF-n and MDA-MB231 cell line were similar, only the MDA-MB231 cell line was independent of both tem-
perature and time of drug administration. This indicates that numerous factors influence permeability of cell 
membranes and further studies are warranted to elucidate possible explanations.
The effect of calcium electroporation around the transitioning temperature on the colon cancer cell line was 
investigated, too. (Further details in Supplementary Data 2 and Supplementary Fig. S2).
Lipidomics: Membrane composition. Mass spectrometry based lipid analysis was performed on preparations of 
plasma membranes (Fig. 3). The lipidomics data represented both the inner and outer membrane leaflet, thus we 
did not have information of the distribution of the lipids between the two leaflets.
The cellular lipodome of the three cell lines was compared focusing on differences with regards to levels of 
phosphatidylserine (PS) and other negatively charged lipids, since calcium can bind to these lipids45,46, but no 
differences were found between the three cell lines (Fig. 3, left panel – light and dark blue).
The only remarkable difference between the investigated normal cell line HDF-n and the two investigated 
malignant cell lines HT29 and MDA-MB231 were the content of phosphatidylethanolamine (PE) where the nor-
mal cell line HDF-n contained more PE than the two malignant cell lines HT29 and MDA-MB231 (Fig. 3, left 
panel – brown), however the significance of this is to our knowledge not previously investigated and further 
studies are warranted.
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Interestingly, one factor separated the colon cancer cell line from the breast cancer cell line and the normal 
cell line. The colon cancer cell line showed much higher levels of the lipids in ether form, e.g. phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) in their ether form (PC O- and PE O-) than the two other cell lines 
(Fig. 3, left panel – green). As ethers are synthesized from esters the cell line consequently has lower levels of these 
lipids in ester form (Fig. 3, left panel – light grey). PC O- and PE O- are not negatively charged, but their structure 
is believed to contribute to more membrane stiffness34 and a higher threshold of electropermeabilization35 than 
their counterparts containing ester-links47,48. This may contribute to the dependency of temperature and time of 
drug administration observed in treatment of the colon cancer cell line with calcium electroporation.
Flow cytometric analysis of expression of phosphatidylserine in the outer leaflet of the cell membrane. Flow cyto-
metric analysis was performed to investigate if any differences existed between the three cell lines in their exposure 
of PS in the outer leaflet of their plasma membranes. For each cell line untreated cells were stained with Annexin 
V-FITC and PI. The Annexin V stain is much used to detect apoptosis; however here we investigated untreated 
cells, under the assumption that the PS observed in the outer membrane leaflet was not a result of apoptosis but 
related to the composition of the cell membrane. Concomitant PI staining was used to indicate cell death.
Figure 4 presents the distribution between Annexin V−/PI− cells, PI+ cells, and Annexin V+/PI− cells in 
all three cell lines and representative dot-plots are displayed in Supplementary Fig. S3. PI-positive cells were con-
sidered damaged cells with compromised membrane integrity (no statistical significant difference between cell 
lines). Subsequently only Annexin V+/PI− cells were considered positive for exposure of PS in the outer leaflet 
of their cell membranes. Thus, the number of PS exposing cells may actually be higher than what we report as the 
damaged cells that were excluded from the count of PS exposing cells, may have exposed PS in the outer leaflet of 
their membrane. Staining of the HT29 cell line resulted in a significantly higher percentage of Annexin V+/PI− 
cells compared to MDA-MB231 and HDF-n cells (p < 0.05). Calcium has previously been shown to interact with 
PS in a cell membrane46 thereby stabilizing the membrane45. It is therefore interesting that a high amount of HT29 
cells expose PS in its outer membrane leaflet and that this cell line was sensitive to changes in time of calcium 
addition during the calcium electroporation process. For the HT29 cell line 33.1% of cells were Annexin V+/PI− 
showing that one third of the HT29 cells exposed PS in the outer leaflet of their cell membranes. This indicates a 
level of heterogeneity in composition of cell membranes in the HT29 cell line.
Figure 2. Heat capacity profiles of the three investigated cell lines. Heat capacity profiles of HT29 (colon cancer 
cell line; left), MDA-MB231 (breast cancer cell line; middle), and HDF-n (normal dermal fibroblast cell line; 
right). Solid lines represent the first scan over the full temperature range (0–90 °C). Dashed lines represent the 
second calorimetric scan over the full temperature range. The protein peaks have disappeared (because the 
proteins have denaturated in the first scan over the full range of temperatures) while the lipid peaks remain. The 
amplitude of the lipid peaks can change between scans due to subtraction of base line but the position of the 
peak (temperature) is more constant between scans. The vertical line represents the physiological temperature. 
Bottom panel: enlargement of the top panel from 0–40 °C, where approximate transition temperatures are 
indicated.
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Untreated samples of the MDA-MB231 cell line and the HDF-n cell line had a percentage of PS-positive cells 
of approximately 3% (MDA-MB231 3.35% and HDF-n 3.07%; no significant difference). Thus, the amount of 
MDA-MB231 and HDF-n cells exposing PS in the outer leaflet of the cell membranes was significantly lower than 
the HT29 cells (p < 0.05). Only 6–10% of cells were PI positive (dead cells) and no significant difference were 
observed between cell lines.
Figure 3. Lipidomics. The left panel displays the distribution of lipid classes in the membranes of three cell 
lines: HT29 (colon cancer), MDA-MB231 (breast cancer), and HDF-n (normal fibroblast cell line). Amounts 
are given in mol%. No difference in the content of negatively charged lipids (dark blue and light blue) was 
found between the cell membranes of the three cell lines. Neither did the membranes of the cell lines differ with 
regards to their content of phosphatidylserine (PS). HT29 showed much higher levels of the lipids in ether form, 
e.g. phosphatidylcholine (PC) and phosphatidylethanolamine (PE) in their ether form (PC O- and PE O-) than 
MDA-MB231 and HDF-n. The right panel displays the content of species of PC in the plasma membranes of 
the three cell lines in the form of esters (PC; top panel) and in the form of ethers (PC O-; bottom panel). The 
experiment was independently repeated, confirming the initial result.
Figure 4. Flow cytometric analysis of phosphatidylserine (PS) exposure. Percentage of PS-exposing cells in 
the outer leaflet of the plasma membrane in each cell line. Untreated cells were stained with propidium iodide 
(PI) and Annexin V before flow cytometric analysis. The Annexin V stain is much used to detect apoptosis; 
however here we investigated untreated cells under the assumption that the PS observed in the outer leaflet was 
not a result of apoptosis but related to the composition of the cell membrane. Thus, Annexin V+/PI− show 
the percentage of cells exposing PS in the outer membrane. PI+ show the percentage of dead cells. Mean + SD, 
n = 3–4, each performed as individual experiments.
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Discussion
In this study, we have investigated permeabilization efficacy (determined by cell death due to calcium or bleomy-
cin internalization) and dependence on temperature and time of drug administration (pre or post pulse). These 
results have been supplemented with data from lipidomics analyses, differential scanning calorimetry, and analy-
sis of the outer membrane leaflet by flow cytometry, and a hitherto unveiled heterogenity between membranes of 
cell lines was observed, which might affect the sensitivity to electroporation-based therapies.
The results evidence that temperature has a significant influence on the effect of calcium electroporation and 
for the HT29 cell line also on the effect of bleomycin electroporation. The effect of temperature on electroperme-
abilization has previously been described by Kanduser et al.49 and an increase in temperature has recently been 
shown to increase gene expression following gene electrotransfer in addition to permit a decrease in the electrical 
field applied in gene electrotransfer in vivo50. The observed differences in effect of electroporation-based treat-
ments might be more pronounced with higher temperature differences between samples. For the HT29 and the 
HDF-n cell line treatment effect of calcium-bleomycin electroporation was similar to that of calcium electropo-
ration. This similarity in results between the two treatments could indicate that calcium, when combined with 
bleomycin and electroporation, may alter the degree or duration of the permeabilized state, and may in this way 
alter intracellular uptake of bleomycin.
The heat capacity profile of the HT29 cell line might contribute to the explanation for the temperature 
and time of addition dependent results of calcium electroporation and calcium-bleomycin electroporation. 
Permeability of a lipid membrane is highest around the transition phase of that membrane, and the temperature 
at which this transition occurs, is influenced by, among others, the concentration of calcium and anesthetics. 
Anesthetics lower the transition temperature whereas calcium elevates it35,36,45,51. The effect of calcium on the 
heat capacity profile and hence on the permeability of a cell membrane may in part explain why treatment with 
calcium electroporation and calcium-bleomycin electroporation was not conclusively optimal at 21 °C; calcium 
results in a shift of the heat capacity curve towards higher temperatures meaning that the temperature resulting in 
the phase transition of the HT29 cell membrane was elevated and approaching 27 °C and that the permeability of 
the cell membrane at 17 °C was lowered. This was corroborated by the data from treatment of the HT29 cell line at 
21 °C. This temperature seemed to be optimal for bleomycin electroporation but not for calcium electroporation 
and calcium-bleomycin electroporation (Supplementary Data 2, Supplementary Fig. S2).
As for the two other cell lines, the heat capacity profiles did not exhibit transition within the temperature 
range investigated. However, the effect of calcium on the heat capacity profiles is not investigated in this study and 
further studies to evaluate the effect of calcium on the heat capacity profiles of the cell lines are warranted. In the 
presence of calcium, any phase transition will occur at a higher temperature and this may explain why the effect of 
calcium electroporation and calcium–bleomycin electroporation on the HDF-n cell line was highest at 37 °C. The 
heat capacity of the MDA-MB231 cell line also displayed distinct phases, and the fact that treatment of this cell 
line was entirely independent of changes in temperature therefore cannot be explained by its heat capacity profile.
As the composition of a membrane highly determines its permeability, we also investigated the plasma mem-
branes of the three cell lines using lipidomics. A remarkable difference in the content of lipids in ether form was 
found between the three cell lines with the HT29 cell line containing a much higher level of the lipids PE and PC 
in the form of ethers than the other two cell lines. The structure of ethers favors more dense packing than that of 
esters and studies on vesicles have shown that the threshold for electropermeabilization increases when the ratio 
of ethers to esters increases47,48. Under conditions used in the clinic, i.e. adding calcium prior to electroporation, 
the toxicity of calcium electroporation and calcium-bleomycin electroporation was similar for all three cell lines. 
However, when changing the temperature or adding calcium after electroporation the viability of the HT29 cell 
line was particularly affected. The sensitivity of this cell line to a degradation of treatment conditions may be due 
to an underlying lower membrane permeability of this cell line, and further studies may elucidate other influenc-
ing elements.
No difference in the total content of PS was found between the three cell lines in lipidomics, which however 
only provided information on the total distribution of lipids in the plasma membrane and did not distinguish 
between the inner and outer membrane leaflet.
One factor that is known to generally differ between normal and malignant cells is the fraction and localiza-
tion of the negatively charged phospholipid PS52. Plasma membrane asymmetry is an important feature of normal 
cells, in which PS is almost exclusively localized in the inner leaflet of the cell membrane, unless the cells are 
undergoing apoptosis, where PS is relocated to the outer leaflet53. In many malignant cells this plasma membrane 
asymmetry is lost resulting in the localization of PS in the outer membrane leaflet, also when the cells are not 
undergoing apoptosis54–57. Calcium is known to interact with PS thereby stabilizing the cell membrane45,46 and 
exposure of PS in the outer cell membrane leaflet may therefore influence the effect of calcium electroporation. 
A very small amount of the normal dermal fibroblasts was found to expose PS in its outer cell membrane leaflet. 
This was also the case for the breast cancer cells, however 33.1% of the colon cancer cells exposed PS in the outer 
leaflet of their cell membranes. Thus, on the cell line with the highest amount of cells exposing PS in the outer 
leaflet, there was a difference in treatment effect of calcium electroporation and calcium-bleomycin electropora-
tion between administration of calcium pre- or post-pulses regardless of temperature. A similar time of addition 
dependency was not observed on the other two cell lines or on the HT29 cell line with bleomycin electropora-
tion. It could be speculated 1) that calcium when added before electroporation alters the degree or duration of 
the permabilized state on the HT29 cell line and 2) that the electrical pulses ameliorate this proposed stabilizing 
effect of calcium on the HT29 cell membrane, due to the higher PS-exposure, but further studies are warranted.
In the investigated normal cell line only a few cells were positive for PS-exposure; however treatment of this 
normal cell line with calcium electroporation and calcium-bleomycin electroporation at 37 °C resulted in depend-
ence of time of drug addition. As this particular normal cell line is known to have a high membrane repair 
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capacity29, the dependence on time of calcium addition in calcium electroporation and calcium-bleomycin elec-
troporation at 37 °C may be related to efficient membrane repair in this cell line.
The influence of temperature and time of calcium administration on the effect of calcium electroporation has 
not previously been investigated and its determination is important in the clinic as it might lead to optimization 
of the treatment. Though an exact temperature control is difficult to obtain in the clinic, the cooling effect of cold 
anesthetics and cold calcium can be circumvented by letting the drugs normalize to room temperature prior to 
injection. Calcium and anesthesia have contrasting effects on the melting transition of cell membranes and the 
combined effects of these drugs on the permeability of cell membranes would be very interesting to investigate.
In conclusion, we have shown that temperature and time of calcium administration influence the effect of 
calcium electroporation; and importantly that this effect is cell line dependent. We found marked differences in 
the composition of membranes in these cell lines using lipidomics analyses, in particular a high concentration 
of ether lipids in the cell line showing the most dynamic response with regards to temperature dependency. 
Furthermore, difference in lipids in the outer leaflet of the cell membrane may influence the level of permeabili-
zation. As calcium is a cation that may interact with lipids in the outer membrane leaflet, the influence of outer 
leaflet lipid composition on the level of permeabilization may in particular pertain to calcium electroporation. 
This study indicates that membrane composition might influence the effect of electroporation based therapies. 
Other factors of cell membrane composition than those investigated in this study may also affect sensitivity of 
treatment and further studies are warranted.
Materials and Methods
Cell culture. Two human cancer cell lines and a normal human cell line were used: HT29 (ATCC #HTB-38), 
a human colorectal adenocarcinoma, MDA-MB231 (ATCC #HTB-26), a human breast adenocarcinoma, and 
HDF-n, a normal neonatal primary dermal fibroblast (kindly provided by Dr. Marie-Pierre Rols, Institute of 
Pharmacology and Structural Biology, IPBS, Toulouse, France) for which passages were limited to 10. HT29 was 
grown in RPMI-1640 culture medium (Gibco, Invitrogen) and MDA-MB231 and HDF-n were grown in DMEM 
culture medium (Gibco, Invitrogen). The culture medium for all cell lines was added 10% fetal calf serum (Gibco, 
Invitrogen), penicillin (100 U/ml) and streptomycin (100 µg/ml). The cells were grown in an incubator at 37 °C 
with 5% CO2. All cell lines tested negative for mycoplasma.
Authentication: The cancer cell lines were authenticated by short tandem repeat profiling (LGC Standards) 
which showed perfect match for the HT29 cell line and a match in 7 out of 9 profile loci (loci D7 and VWA had 
lost a peak) for the MDA-MB231 cell line and these two profile changes have been assessed not to influence the 
results of these experiments.
electroporation experiments. After trypsination and wash, cells were suspended in HEPES buffer 
(10 mM HEPES (Lonza), 250 mM sucrose, and 1 mM MgCl2 in sterile water).
A volume of 270 µl of cell suspension (6.1 × 106 cells/ml) was added to a cuvette containing either 30 µl of 
HEPES or 30 µl of drug dissolved in HEPES (final concentration of cells 5.5 × 106 cells/ml) and incubated for 
5 min in a heating block (Grant, QBD2) at either 17 °C, 21 °C, 27 °C, or 37 °C before electroporation. Temperature 
of the samples was measured and was within +/−5 °C of the temperature of the heating block with 17 °C and 
37 °C having the largest variations. Electroporation took place in 4 mm cuvettes with aluminium electrodes 
(Molecular BioProducts, Inc.), and pulses were delivered by a square wave electroporator (BTX T820) with the 
following electroporation parameters: 8 pulses of 99 µs, 1 Hz, and 1.2 kV/cm (applied voltage to electrode distance 
ratio). Drugs were dissolved in HEPES buffer and added to a final concentration of: CaCl2 5 mM, and bleomy-
cin (Bleomycin Baxter) 10 µM, before or after electroporation. Both doses were chosen as it was found in initial 
studies17,23,26 that they result in more than 80% cell kill when combined with electroporation. For samples where 
drug was added after electroporation, cells were electroporated with HEPES buffer followed by addition of 50 µl 
drug dissolved in HEPES buffer at the designated time. No mixing of drug and sample was done before or after 
electroporation, and drugs were added by placing the pipette at the bottom of the cuvette. The added volume 
before electroporation constituted 10% of the total volume of the sample. Thus, 30 µl drug or HEPES buffer and 
270 µl cells were added to the cuvette followed by electroporation. If drug was added after electroporation this was 
done in a volume of 50 µl at the designated time. In samples where drug was added before electroporation, 50 µl 
HEPES buffer was added before transferring to medium to secure the same cell concentration in all samples. All 
samples were incubated at the designated temperature for 5 min before electroporation, independent on time of 
drug addition. Prior to addition to cell suspension drugs were kept at room temperature.
Samples were divided into 5 groups according to the time point at which drug was added relative to electro-
poration: 5 min before electroporation, 1 s before electroporation, 15 s after electroporation, 30 s after electropo-
ration, or 60 s after electroporation. Each group contained 3 samples: one treated with calcium electroporation, 
one treated with bleomycin electroporation, and one treated with calcium and bleomycin combined with elec-
troporation (calcium-bleomycin electroporation). An additional group consisted of 5 control samples: calcium, 
bleomycin, calcium and bleomycin (all three without electroporation), electroporation without drug, and an 
untreated control.
After electroporation or no electroporation, samples were incubated for 15 min at 37 °C and 5% CO2 in the 
cuvettes before transfer to 5 ml culture medium. Then, 100 µl were seeded in a 96 well plate (3.1 × 104 cells per 
100 µl). MTS assay was performed 21–25 hours after treatment using a microplate reader (Synergy HT, BioTek) 
and Gen5 microplate reader software (BioTek).
Heat capacity of cell membranes. Differential scanning calorimetry (DSC) was performed from mem-
brane preparations of the three cell lines. Cells were continually harvested and frozen at −80 °C until a sufficient 
amount for DSC was obtained.
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Membranes were prepared from thawed samples. Lysis buffer (Natriumchlorid 137 mM, Tris 20 mM, Nonidet 
P40 1%, Glycerol 10%, PMSF Sigma P7626 1 mM, AProtinin Sigma A6103 10 µg/ml, Natrium metavanadat Sigma 
59008 0.5 mM, Leupeptin Sigma L2882 1 µg/ml) was added to each cell pellet. Cells were transferred to 2 ml 
Eppendorf tubes containing a steel ball and mechanically homogenized for 2 min at 20 Hz using a Tissue Lyser 
(QIAGEN). Cells were then centrifuged (VWR Microstar 17R) at 300 g for 10 min causing precipitation of the 
nuclei. The supernatant was then centrifuged (VWR Microstar 17R) at 3000 g for 10 min causing precipitation of 
mitochondria. The supernatant was lastly centrifuged (Sigma 3K20) at 40,000 g for 1.5 hours causing formation 
of plasma membrane pellets. All centrifugations took place at 4 °C. Membrane pellets were resuspended in PBS 
(0.7 ml). Membrane preparations were kept at 4 °C for 1–3 days until analysis by heat calorimetry.
Differential scanning calorimetry: Samples were degassed under high vacuum. Calorimetric scans were per-
formed on a Malvern MicroCal VP-DSC (Northampton, MA) differential scanning calorimeter. Heating rates 
were kept at 20 °C/hour, filtering period was 5 seconds and feedback was set to none. PBS buffer was used as a 
reference. Each scan was run on 0.5152 ml of sample (which is the size of the calorimeter cell) containing between 
12 and 32 mg of dry matter. The weight of substance was measured by drying the sample under air stream and 
high vacuum. First, samples were equilibrated in one or two scans from 0–38 °C, to avoid any differences due to 
the time samples were kept at 4 °C. These scans were discarded. Then, the full range scans were performed. No sig-
nal averaging or other forms of data smoothing were applied to the thermograms. The data was processed using 
IgorPro. Between scans of different samples, calorimetric cells were thoroughly cleaned with 37% HCl.
FACS. Expression of phosphatidylserine (PS) in the outer leaflet of the cell membrane was investigated by flow 
cytometry using Mebcyto Apoptosis kit (MBL, #4700).
Untreated cells in HEPEs buffer (500,000 cells in 90 μl) were centrifuged at 1000 rpm for 3 min, the superna-
tant was removed and cells were resuspended in 85 µl binding buffer (part of the kit).
Annexin V-FITC (10 µl) and propidium iodide (PI, 5 µl, 100 µg/ml) were added and samples were incubated 
in the dark at room temperature for minimum 15 min. Then, 400 µl binding buffer was added to all samples 
and transferred to FACS tube before flow cytometric analysis at room temperature using FACS Calibur (Becton 
Dickinson) counting 10,000 events for each sample.
Unstained, only Annexin V stained and only PI stained samples of all three cell lines were used to adjust the 
settings of the instrument for each cell line. Each sample was run in duplicates or triplicates and the assay was per-
formed three-four times for each cell line, thus n = 3–4. For the data analyses, the gating was set so all events were 
selected except the debris. The events were divided in 4 quadrants with respectively PI-positive vs PI-negative 
and Annexin V-positive vs Annexin V-negative based on the control samples (unstained, only Annexin V stained 
and only PI stained). The percentages of gated events were used for the statistical analyses and graphs. PI staining 
indicate cell death. Representative dot-plots are displayed in Supplementary Fig. S3.
Lipidomics. Lipidomics was performed on membrane preparations. Cell cultures were harvested after growth 
at 37 °C. Membranes were prepared as described in the above section of heat calorimetric experiments to collect 
plasma membranes. After preparation, the membrane pellets were frozen in liquid nitrogen and stored at −80 °C.
Two-step Lipid Extraction. 75ul of cell membrane lysates were subjected to lipid extraction by a modified 
two-step Bligh and Dyer protocol executed on ice58,59. Briefly, the sample aliquots were spiked with 10 µl inter-
nal lipid standard mix containing 30 pmol CE 15:0-D7, 20 pmol Cer 18:1;2/12:0;0, 200 pmol Chol-D4, 10 pmol 
DAG 12:0/12:0, 20 pmol diHexCer 18:1;2/12:0;0, 25 pmol HexCer 18:1;2/12:0;0, 25 pmol LPA 17:0, 20 pmol LPC 
10:0, 25 pmol LPE 13:0, 15 pmol LPG 17:1, 20 pmol LPI 13:0, 20 pmol LPS 17:1, 25 pmol PA 12:0/12:0, 20 pmol 
PC-OO 18:1/18:1, 25 pmol PE 12:0/12:0, 15 pmol PG 12:0/12:0, 15 pmol PI 8:0/8:0, 20 pmol PS 12:0/12:0, 20 
pmol SHexCer 18:1;2/12:0;0, 20 pmol SM 18:1;2/12:0;0, 10 pmol TAG 17:0/17:0/17:0, and 20 pmol triHexCer 
18:1;2/17:0;0. Samples were extracted with 1000 µl chloroform/methanol (10:1, v/v) and mixed at 2000 rpm for 
15 min at 4 °C. The samples were centrifuged for 2 min at 2000 g to facilitate phase separation. The lower organic 
phase 10:1 was subsequently transferred to a new tube for 30 min vacuum evaporated. The remaining aqueous 
upper phase were reextracted with 1000 µl chloroform/methanol (2:1, v/v) and mixed at 2000 rpm for 15 min at 
4 °C. The lower organic phase 2:1 was transferred to the evaporated 10:1 extract tube and vacuum evaporated for 
60 min. The combined lipid extracts were dissolved in 100 µl chloroform/methanol (1:2, V/V).
Mass Spectrometry. Lipid extracts were subjected to mass spectrometric analysis using a Q Exactive mass spec-
trometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a TriVersa NanoMate (Advion Biosciences, 
Ithaca, NY, USA). 10 µl aliquots of lipid extracts were loaded in 96-well plates, mixed with 12.9 µl of 13.3 mM in 
2-propanol for positive or 10 µl of 0.2% methyl amine chloroform/methanol (1:5, V/V) for negative ion mode 
analysis, respectively. Samples were infused using a back pressure of 1.25 psi and ionization voltage of 0.95 kV for 
positive mode. For negative mode samples were infused using a back pressure of 0.7 psi and ionization voltage of 
−1.06 kV. The acquisition cycle consisted of FT MS and FT MS/MS scans in positive and negative ion mode.
FT MS spectra in positive mode were acquired in low m/z range of 400 to 730 and high m/z range of 575 
to 1201 at the mass resolution of Rm/z 200 = 140,000; automated gain control (AGC) value of 1 × 106; three 
micro-scans; maximum injection time of 150 ms.
FT MS spectra in negative mode were acquired in low m/z range of 400 to 675 and high m/z range of 500 
to 1202 at the mass resolution of Rm/z 200 = 140,000; automated gain control (AGC) value of 1 × 106; three 
micro-scans; maximum injection time of 150 ms.
Sequential FT MS/MS data were acquired using automated gain control (AGC) value of 1 × 105; maximum 
injection time of 150 ms, one microscan, and Rm/z 200 = 35,000.
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FT MS/MS analysis performed in 1.0008 u steps across the m/z range 400.3–1000.8 using a quadrupole ion 
isolation width of 1.2 u and stepped nCE at 18, 28 and 38% for negative mode and for positive mode it was 15, 20 
and 25%.
FT MS – selective ion monitoring (SIM) spectra in positive mode were acquired in m/z range of 396 to 416 
at the mass resolution of Rm/z 200 = 140,000; automated gain control (AGC) value of 1 × 106; maximum injection 
time of 500 ms.
FT MS/MS – targeted parallel reaction monitoring (tPRM) spectra in positive ion mode were acquired for 2 
scans, m/z 404.3887 and 408.4138, at the mass resolution of Rm/z 200 = 35,000; automated gain control (AGC) value 
of 1 × 105; maximum injection time of 500 ms, using a quadrupole ion isolation width of 1.2 u and stepped nCE 
at 13, 18 and 23%.
Annotation of Lipid Species. The annotation of lipid species was as previously described59–61. The glycerophos-
pholipid and glycerolipid species annotated according to their sum composition: <lipid class> <total number of 
C in fatty acid moieties>:<total number of double bonds in fatty acid moieties> (e.g., PC 34:1). The sphingolipid 
species annotated according to their sum composition: <lipid class> <total number of C in the long-chain base 
and fatty acid moiety>:<total number of double bonds in the long-chain base and fatty acid moiety>;<total 
number of OH groups in the long-chain base and fatty acid moiety> (e.g., SM 34:1;2)58,59.
Data Processing, Lipid Identification and quantification. Lipid species detected by high resolution FT MS and FT 
MS/MS analysis were identified using LipidXplorer62,63, and quantified using Excel based calculation. In short, 
lipid species detected by FT MS and annotated by sum composition were quantified by normalizing their inten-
sity to the intensity of an internal lipid standard of identical lipid class and multiplying with the spike amount of 
the internal lipid standard59,64,65.
statistics. In electroporation experiments, differences in viability between the investigated temperatures and 
time points for drug administration were assessed by two-way analysis of variance (ANOVA) using SPSS (ver-
sion 19). The assumption of normally distributed data were tested using a combination of P-P plots, kurtosis and 
skewness, K-S test, and S-W test. In the event of a violation of this assumption, data were log transformed. For 
the assumption of homogeneity of variance, Levene’s test was used. In the event this assumption was violated, an 
adjustment was made using Welch’s F method. Post hoc analyses were conducted using a Bonferroni correction 
for multiple comparisons when assumptions for parametric testing were met. Games-Howell was used for post 
hoc analyses, where homogeneity of variance was violated. Differences in Annexin V and PI levels were assessed 
by one-way ANOVA using SAS (version 9.4). The assumption of normally distributed data were tested using P-P 
plots and for the assumption of homogeneity of variance, Levene’s test was used. No violation of the assump-
tions were seen. The alpha criteria for significance were set at 0.05 for all tests. Results are displayed in graphs as 
mean + 1 SD.
Data Availability
All data are available via contact to corresponding author.
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